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Aims: Deprescribing of antihypertensive drugs is recommended for some older patients
with polypharmacy, but there is little evidence to inform which drug (or dose) should be
withdrawn. This study used data from the OPTiMISE trial to examine whether short-term
outcomes of deprescribing vary by drug class and dose of medication withdrawn.
Methods: The OPTiMISE trial included patients aged ≥80 years with controlled systolic
blood pressure (SBP; <150mmHg), receiving ≥2 antihypertensive medications. This study
compared SBP control, mean change in SBP and frequency of adverse events after
12 weeks in participants stopping one medication vs. usual care, by drug class and
equivalent dose of medication withdrawn. Equivalent dose was determined according to
the defined daily dose (DDD) of each medication type. Drugs prescribed below the DDD
were classed as low dose and those prescribed at ≥DDD were described as higher dose.
Outcomes were examined by generalized linear mixed effects models.
Results: A total of 569 participants were randomized, aged 85 ± 3 years with controlled
blood pressure (mean 130/69mmHg). Within patients prescribed calcium channel
blockers, higher dose medications were more commonly selected for withdrawal (90
vs. 10%). In those prescribed beta-blockers, low dose medications were more commonly
chosen (87 vs. 13%). Withdrawal of calcium channel blockers was associated with an
increase in SBP (5 mmHg, 95%CI 0–10mmHg) and reduced SBP control (adjusted RR
0.89, 95%CI 0.80–0.998) compared to usual care. In contrast, withdrawal of beta-
blockers was associated with no change in SBP (−4mmHg, 95%CI −10 to 2mmHg)
and no difference in SBP control (adjusted RR 1.15, 95%CI 0.96–1.37). Similarly,
withdrawal of higher dose medications was associated with an increase in SBP but no
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change in BP control. Withdrawal of lower dose medications was not associated with a
difference in SBP or SBP control. There was no association between withdrawal of specific
drug classes and adverse events.
Conclusion: These exploratory data suggest withdrawal of higher dose calcium channel
blockers should be avoided if the goal is to maintain BP control. However, low dose beta-
blockers may be removed with little impact on blood pressure over 12-weeks of follow-up.
Larger studies are needed to confirm these associations.
Keywords: deprescribing, older adults, hypertension, polypharmacy, Multi-morbidity, beta-blockers, calcium
channel blockers, defined daily dose
INTRODUCTION
Antihypertensive treatment is effective at preventing stroke and
cardiovascular disease in older high-risk patients with
hypertension (Beckett et al., 2008; SPRINT Investigators et al.,
2015; Thomopoulos et al., 2018) and many individuals aged
80 years or older are prescribed therapy (Sheppard et al.,
2012). Such patients are also more likely to live with multiple
long-term conditions (Barnett et al., 2012) leading to
polypharmacy, which increases an individual’s likelihood of
hospitalization due to adverse events (Pirmohamed et al.,
2004; Sato and Akazawa, 2013). It is unclear whether intensive
blood pressure lowering is safe and effective in older patients with
multi-morbidity and frailty. Previous trials have found that frailty
has no modifying effect on the efficacy of blood pressure lowering
in older patients (Warwick et al., 2015; Williamson et al., 2016),
however, such trials may not have included very frail patients seen
in the general population (Sheppard et al., 2020a; Sheppard et al.,
2020b). In contrast, evidence from meta-analyses of randomized
controlled trials (Bejan-Angoulvant et al., 2010; Thomopoulos
et al., 2016) and observational studies (Tinetti et al., 2014; Benetos
et al., 2015; Mansfield et al., 2016) suggests that aggressive
lowering of systolic blood pressure (i.e. to less than 130 mm
Hg) and multiple antihypertensive prescriptions may be harmful,
particularly in older patients with polypharmacy and multi-
morbidity (Tinetti et al., 2014; Thomopoulos et al., 2016).
Guidelines therefore recommend using clinical judgment
when prescribing in frail older patients (National Heart
Foundation of Australia, 2016; National Guideline Centre,
2019; Liu et al., 2020), emphasizing a personalized approach
to care which might include attempts to improve quality of life
through deprescribing (Benetos et al., 2016; National Guideline
Centre, 2016). The Optimizing Treatment for MIld Systolic
hypertension in the Elderly (OPTiMISE) trial (Sheppard et al.,
2020c) examined a structured approach to antihypertensive
medication reduction in older patients with multi-morbidity
and controlled systolic hypertension, prescribed two or more
antihypertensives. The overarching aim of the OPTiMISE trial
was to reduce polypharmacy without blood pressure becoming
uncontrolled. The trial showed that a strategy of medication
reduction results in similar proportions of patients with
controlled systolic blood pressure (<150 mm Hg) at 12 weeks
when compared to continuing antihypertensives. No differences
were observed in serious adverse events or quality of life, although
systolic/diastolic blood pressure did increase modestly by 3/2 mm
Hg in the medication reduction group (Sheppard et al., 2020c).
There is little evidence to guide antihypertensive deprescribing
(Krishnaswami et al., 2019), and therefore physicians
participating in the trial were instructed to decide which
antihypertensive should be removed based on advice from a
medication reduction algorithm (Figure 1). The present study
aimed to examine whether this choice was associated with blood
pressure changes and adverse events in the trial.
METHODS
Design
This was a post-hoc exploratory analysis of data from the
OPTiMISE trial of antihypertensive medication reduction
(Sheppard et al., 2020c). All participants randomized in the
trial, who did not withdraw consent, were included in the
analysis. The trial was approved by an NHS Research Ethics
Committee (South Central - Oxford A; ref 16/SC/0628) and the
Medicines and Healthcare products Regulatory Agency (MHRA;
ref 21,584/0371/001-0001). All participants gave written
informed consent. Details of patient recruitment and data
collection are described in detail elsewhere (Sheppard et al.,
2018; Sheppard et al., 2020c).
Study Population
Individuals were eligible if they were aged ≥80 years, with systolic
blood pressure at baseline <150 mmHg (based on themean of the
second and third readings taken, after 5 min of rest) and
prescribed two or more antihypertensive treatments for at
least 12 months. Recruiting primary care physicians were
asked to only enroll patients whom in their opinion might
potentially benefit from medication reduction due to existing
polypharmacy, co-morbidity, non-adherence or dislike of
medicines, and/or frailty. This clinical judgment was
considered important given the current lack of evidence as to
who should be targeted for such an intervention. Patients with a
history of heart failure due to left ventricular dysfunction or
myocardial infarction/stroke in the preceding 12 months,
secondary hypertension or lacking in capacity to consent were
excluded.
Potentially eligible patients were identified from searches of
electronic health records in participating sites and sent letters of
Frontiers in Pharmacology | www.frontiersin.org April 2021 | Volume 12 | Article 6190882
Sheppard et al. Optimal Antihypertensives for Deprescribing
invitation. Those expressing an interest attended a screening
appointment.
Randomization and Blinding
Participants were allocated (1:1 allocation ratio) to one of the two
study groups using a non-deterministic minimization algorithm,
with minimization designed to balance site and baseline systolic
blood pressure, via a fully validated, web-based, password
protected system. Investigators and participants were unaware
of the treatment allocation prior to consent and baseline
assessments. The trial used an unblinded design with patients
and investigators not masked to randomization group.
Medication Reduction Intervention
Participating primary care physicians reviewed each
participant’s medication regimen before randomization and
decided which antihypertensive would be removed if they
were allocated to medication reduction, using a pre-specified
algorithm (Figure 1). This algorithm recommended reducing
medications in reverse of the C + A + D NICE treatment
algorithm. Following an adverse event possibly related to
abrupt discontinuation of a beta-blocker, gradual withdrawal
of these medications was encouraged to avoid rebound
adrenergic hypersensitivity. For individuals randomized to
medication reduction, physicians were asked to monitor
blood pressure at a 4 week follow-up visit and reinstate
treatment if it consistently rose above 150 (systolic) or 90
(diastolic) mm Hg, or in the case of adverse events or
accelerated hypertension. Patients in the control group were
given usual care and no medication changes were mandated.
Outcomes
Outcomes examined in this analysis were not pre-specified before
the end of the trial and should be treated as exploratory.
Outcomes included between group differences in systolic
blood pressure control, adverse events and change in systolic
and diastolic blood pressure at follow-up by drug class and dose
of medication chosen for withdrawal. Adverse events were
defined as any clinical event occurring during follow-up,
regardless of whether it was deemed to be possibly, probably
or definitely related to the intervention by the treating physician.
Systolic and diastolic blood pressure were defined as the mean of
the second and third consecutive readings taken at 1 min
intervals. Measurements were taken in the seated position,
using the clinically validated BpTRU blood pressure monitor
(Mattu et al., 2004) after a period of 5 min of rest.
Definition of Subgroups
For each analysis by drug class, groups were determined
according to drug classifications in the British National
Formulary (BNF) (Royal Pharmaceutical Society, 2020).
Equivalent dose of medication was determined by converting
the doses of each drug chosen for withdrawal into a common unit
of measure using theWorld Health Organisation (WHO) defined
daily dose (DDD) for each medication type (World Health
Organisation (WHO) Collaborating Centre for Drug Statistics
FIGURE 1 |Medication reduction algorithm given to general practitioners participating in the Optimize trial NICE National Institute for Health and Care Excellence.
Contraindicated medications described in the STOPP START criteria (Gallagher et al., 2008). Figure adapted from previous publications about this trial (Sheppard et al.,
2018; Sheppard et al., 2020c).
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Methodology, 2020). For example, the DDD for Ramipril is
2.5 mg (World Health Organisation (WHO) Collaborating
Centre for Drug Statistics Methodology, 2020), so if a drug
was prescribed at 1.25 mg, it would be classified in the present
analysis as having a medication equivalent dose of 0.5. For the
purposes of these analyses, participants were divided into two
groups according to the equivalent dose of medication chosen for
withdrawal; low dose medications were those prescribed at less
than the DDD (i.e. an equivalent medication dose of <1). Higher
dose medications were those prescribed at the DDD or higher
doses (i.e. an equivalent medication dose of ≥1).
Covariates
Data relating to participant demographics, body mass index, blood
pressure, cognition (Montreal Cognitive Assessment [MoCA] Score)
(Nasreddine et al., 2005), functional independence (modified Rankin
score) (Sulter et al., 1999), frailty (electronic/Searle Frailty Index)
(Searle et al., 2008; Clegg et al., 2016), past medical history and
treatment prescriptions were collected at baseline via participant
questionnaires and review of the electronic health record.
Predictors of physician drug choice were selected to reflect trial
guidance provided on medication reduction. This included the
number of pre-existing medication prescriptions, concurrent
morbidities, frailty (defined using the electronic frailty index)
(Clegg et al., 2016), age, sex and systolic blood pressure at
baseline. Multivariate models examining the association between
medication withdrawal and outcomes were adjusted for factors
found to be predictive of medication choice for withdrawal and
missing follow-up data, including baseline systolic blood pressure,
gender, MoCA score (Nasreddine et al., 2005), EQ-5D-5L Index
(Herdman et al., 2011), Searle Frailty Index (Searle et al., 2008) and
primary care site.
Statistical Analysis
Descriptive statistics were used to describe the study population, the
proportion of participants maintainingmedication reduction and the
proportion experiencing no increase in systolic blood pressure in the
intervention group at follow-up. These were estimated by drug class
and dose of medication chosen for withdrawal. Since the choice of
drug to withdraw was not fixed, but rather at the discretion for the
treating physician, multivariable logistic regression was used to
examine predictors of physician drug choice. Statistically
significant predictors were included as factors for adjustment in
the main analysis.
Data from participants examining outcomes of medication
reduction by drug class and medication dose were analyzed
according to the groups to which they were allocated (i.e. by
intention to treat). The relative risk (RR) for blood pressure control
and adverse events between groups were examined by drug class and
medication dose chosen for withdrawal using a robust Poisson
regression model. Each model was adjusted for baseline systolic
blood pressure, covariates predictive of drug choice for medication
withdrawal and those predictive of missing blood pressure data at
follow-up (identified in the preparatory analyses). Since the treating
physician’s choice of medication to withdraw was made prior to
consent and randomization, data were available for all randomized
participants, even though only half went on to have the medication
withdrawn. Therefore, models compared patients withdrawing specific
drugs (the intervention group) to patients where the same drug was
selected for withdrawal, but treatment was actually continued (usual
care). Separate models were fitted according to the drug class and
medication dose chosen for withdrawal. Adjusted mean difference in
change in blood pressure was analyzed by means of generalized linear
mixed model with binomial error and log link, with factors predictive
of physician choice of drug to withdraw and baseline systolic blood
pressure, gender, cognitive function (MoCA Score), EQ-5D-5L Index
and Searle Frailty Index as fixed effects and primary care site as a
random effect.
All data were analyzed using Stata statistical software (version
16.0, College Station TSL, StataCorp, 2019). Data are presented as
means, medians and proportions with 95% confidence intervals
(CI) unless otherwise stated.
RESULTS
Atotal 569patientswere recruited to the trial from69general practices in
Central, Eastern and Southern England. The characteristics of
participants in the trial were broadly comparable to those of a similar
age group in the general population (Supplementary Table S1). Two
hundred and eighty-two participants (49.6%) were randomized to the
medication reduction intervention and 287 participants (50.4%) were
randomized to usual care. A total of 534 (93.8%) participants attended
12-week follow-up and provided valid blood pressure readings.
Participants were well matched for all variables at baseline, with a
mean age of 85 years, multi-morbidity (mean 5.8 morbidities; 98.4%
participants had ≥2 morbidities including hypertension) and
polypharmacy (median four medications; Table 1). Mean blood
pressure at baseline was 130/69mm Hg and individuals were taking
a median of 2 (IQR 2–3) antihypertensive medications.
The most commonly prescribed medications at baseline were
calcium channel blockers (390 participants, 68.5%), ACE inhibitors
(267 participants, 46.9%) and beta-blockers (228 participants, 40.1%).
Calcium channel blockers were typically prescribed in combination
withACE inhibitors (180 participants, 31.6%), angiotensin II receptor
blockers (136 participants, 23.9%) or beta-blockers (131 participants,
23.0%) (Supplementary Table S2). Thiazide and thiazide-like
diuretics were the most common drug class chosen by physicians
for medication reduction (168 participants, 29.6%; 76.4% of those
prescribed thiazide and thiazide-like diuretics) (Table 2). There were
no between group differences in the drug classes chosen for
medication reduction. Higher dose calcium channel blockers,
thiazides and thiazide-like diuretics were more commonly selected
for withdrawal than lower dose medications within these classes
(higher dose 90–91% vs. low dose 9–10%; Table 3 and
Supplementary Table S3). In contrast, low dose beta-blockers
were more commonly chosen for withdrawal than higher dose
beta-blockers (higher dose 13% vs. low dose 87%; Table 3).
Association BetweenMedication Reduction
and Outcomes by Drug Class
After adjusting for factors predictive of drug choice for
medication reduction (Supplementary Table S4), participants
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were less likely to have controlled systolic blood pressure at
follow-up if reducing calcium channel blockers (adjusted RR
0.89 95% CI 0.80–0.998) (Figure 2). Withdrawal of calcium
channel blockers was also associated with an increase in
systolic and diastolic blood pressure (4.7 mm Hg, 95% CI
−0.3–9.7 mm Hg [systolic]; 4.3 mm Hg, 95% CI 1.3–7.3 mm
Hg [diastolic]) (Figure 3). Withdrawal of beta-blockers was
associated with a non-significant reduction in systolic blood
pressure (–4.0 mmHg, 95% CI –9.8 to 1.8 mmHg). There was
no association between withdrawal of specific drug classes and
adverse events (e.g. increased blood pressure, chest pain,
infections, ankle swelling, headache and back pain, etc.).






Age (years), mean (SD) 84.6 (3.3) 85.0 (3.5)
Sex (% female) 131 (46.5%) 145 (50.5%)
Body mass index (mean [SD]; kg/m2) (n  534) 27.2 (4.2) 28.0 (4.3)
Ethnicity (% white) 278 (98.6%) 278 (96.9%)
Current smoker (%) 3 (1.1%) 5 (1.7%)
Alcohol consumption (% reporting drinking alcohol every week) 98 (34.8%) 108 (37.6%)
Montreal cognitive assessment scorea (mean [SD]) (n  562) 24.4 (3.6) 24.0 (4.1)
EQ-5d-5L indexb (mean [SD]) (n  563) 0.78 (0.17) 0.76 (0.17)
Modified rankin scalec (% score >2 [dependant]) (n  540) 36 (12.8%) 42 (14.6%)
Electronic frailty index (eFI),d mean (SD) 0.14 (0.07) 0.15 (0.07)
Fit (eFI 0–0.12; %) 121 (42.9%) 109 (38.0%)
Mild (eFI >0.12–0.24; %) 132 (46.8%) 143 (49.8%)
Moderate (eFI >0.24–0.36; %) 27 (9.6%) 32 (11.1%)
Severe (eFI >0.36; %) 2 (0.7%) 3 (1.0%)
Systolic blood pressure (mmHg), mean (SD) 129.4 (13.1) 130.5 (12.3)
Diastolic blood pressure (mmHg), mean (SD) 68.4 (9.1) 70.1 (8.4)
Orthostatic hypotension (%), (n  525)e 15 (5.7%) 10 (3.8%)
Medical history
Chronic kidney disease (%) 83 (29.4%) 103 (35.9%)
Cancer (%) 67 (23.8%) 68 (23.7%)
Cardiac disease (%)f 61 (21.6%) 61 (21.3%)
Diabetes (%) 48 (17.0%) 53 (18.5%)
Atrial fibrillation (%) 45 (16.0%) 45 (15.7%)
Transient ischemic attack (%) 27 (9.6%) 22 (7.7%)
Stroke (%) 23 (8.2%) 22 (7.7%)
Peripheral vascular disease (%) 6 (2.1%) 9 (3.1%)
Number of morbidities, mean (SD) 5.7 (2.7) 6.0 (2.9)
% ≥2 morbidities (%) 278 (98.6%) 282 (98.3%)
Medication prescriptions
Antihypertensive (%)g 282 (100.0%) 287 (100.0%)
ACE inhibitor (%) 139 (49.3%) 128 (44.8%)
Angiotensin II receptor blocker (%) 99 (35.2%) 115 (40.1%)
Calcium channel blockers (%) 199 (70.6%) 191 (66.6%)
Thiazide and related diuretics (%) 109 (38.7%) 111 (38.7%)
Beta-blockers (%) 112 (39.7%) 116 (40.4%)
Alpha-blockers (%) 41 (14.5%) 39 (13.6%)
Other antihypertensives (%) 19 (6.7%) 35 (12.3%)
Statin (%) 97 (34.4%) 92 (32.1%)
Antiplatelet (%) 58 (20.6%) 53 (18.5%)
Total prescribed medications, median (IQR) 4 (3–7) 4 (3–7)
aScore ranges between 0 and 30 with lower scores representing greater impairment. A score of 26 and over is considered to be normal.
bThe EQ-5D-5L assesses five aspects of health: mobility, self-care, activities, discomfort, and anxiety/depression. EQ-5D-5L index scores were generated using crosswalk approach
which translates the scores for the five EQ-5D-5L items into a single index value. The index value ranges from -0.594 (worse than death) to 1 (full health).
cModified Rankin scale ranges from 0 (no symptoms) to 5 (severe disability).
dThe Electronic Frailty Index has 36 items and is estimated from electronic health records. The index ranges from 0 (fit) to 1 (frail).
eOrthostatic hypotension defined as a decrease in systolic blood pressure of at least 20 mm Hg within 3 min of standing.
fCardiac disease defined as the presence of myocardial infarction, coronary heart disease, angina or heart failure.
gThe sum of percentages for all antihypertensivemedication classes may exceed 100%, since participants had to be taking more than one antihypertensivemedication to be eligible for the trial.
SD  standard deviation.
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Association BetweenMedication Reduction
and Outcomes by Medication Dose
Withdrawal of higher dose medications was associated with an
increase in systolic and diastolic blood pressure (4.7 mmHg, 95%
CI 1.8–7.5 mmHg [systolic]; 2.4 mm Hg, 95% CI 0.7–4.0 mm Hg
[diastolic]) but no difference in blood pressure control (adjusted
RR 0.98 95% CI 0.92–1.46) (Figure 4). Withdrawal of low dose
medications was not associated with any difference in systolic
blood pressure (–0.5 mmHg, 95% CI –5.0 to 4.1 mmHg) or blood
pressure control (adjusted RR 1.00 95% CI 0.89–1.13) between
groups. However, withdrawal of low dose medications was
associated with an increased risk of adverse events (adjusted
RR 1.56 95% CI 1.14–2.14).
Maintenance of Medication Reduction
All 282 patients randomized to the intervention arm of the trial
attempted to withdraw the medication chosen by their primary
care physician. Overall, 91 (32.4%) had their medication
reintroduced and 101 (35.9%) experienced no increase in
systolic blood pressure at 12 weeks follow-up (Supplementary
Table S5). The highest proportion of participants maintaining
medication reduction and experiencing no increase in systolic
blood pressure were those reducing ACE inhibitors (79.4 and
44.1% respectively) and beta-blockers (80.6 and 55.6%
respectively). There was no difference in the proportion
maintaining medication reduction between those withdrawing
higher dose medications and those withdrawing low dose
medications (higher dose 66.3% vs. low dose 70.4%).
DISCUSSION
The OPTiMISE trial (Sheppard et al., 2020c) found that one
antihypertensive medication could be withdrawn in the majority
of participants without substantial change in blood pressure
control at 12 weeks follow-up. This post-hoc exploratory
analysis found some evidence to suggest that beta-blockers in
particular, especially those prescribed at low doses, may be
withdrawn with little or no increase in blood pressure. This
makes them a potential target for deprescribing in older
patients with no other compelling indication for therapy.
Withdrawal of higher dose calcium channel blockers was
associated with a reduced likelihood of blood pressure control
at follow-up, despite these medications being less likely to be
selected for medication reduction in participants with higher
TABLE 2 | Total proportion of medications prescribed and selected for medication reduction by randomized group.
Drug class Medications prescribed Medications selected for withdrawal
Total (%) Intervention
(%)











Calcium channel blocker 390 (68.5%) 199 (70.6%) 191 (66.6%) 131 (23.1%) 33.6 64 (22.8%) 67 (23.4%)
ACE inhibitor 267 (47.0%) 139 (49.3%) 128 (44.8%) 68 (12.0%) 25.5 34 (12.1%) 34 (11.9%)
Angiotensin II receptor blocker 214 (37.7%) 99 (35.2%) 115 (40.1%) 55 (9.7%) 25.7 27 (9.6%) 28 (9.8%)
Thiazide or thiazide-like
diuretic
220 (38.8%) 109 (38.8%) 111 (38.8%) 168 (29.6%) 76.4 88 (31.3%) 80 (27.8%)
Beta-blocker 228 (40.1%) 112 (39.7%) 116 (40.6%) 77 (13.6%) 33.8 36 (12.8%) 41 (14.3%)
Alpha-blocker 80 (14.1%) 41 (14.5%) 39 (13.6%) 43 (7.6%) 53.8 22 (7.8%) 21 (7.3%)
Other antihypertensive 54 (9.5%) 19 (6.7%) 35 (12.2%) 25 (4.4%) 46.3 10 (3.6%) 15 (5.2%)
ACE  angiotensin converting enzyme.
TABLE 3 | Antihypertensive medications chosen for withdrawal at baseline by drug class and medication dose.















Calcium channel blockers 13 (9.9%) 9 (6.9%) 4 (3.1%) 118 (90.1%) 55 (42.0%) 63 (48.1%)
ACE inhibitors 18 (26.5%) 11 (16.2%) 7 (10.3%) 50 (73.5%) 23 (33.8%) 27 (39.7%)
Angiotensin II receptor blockers 18 (32.7%) 6 (10.9%) 12 (21.8%) 37 (67.3%) 21 (38.2%) 16 (29.1%)
Thiazide and thiazide-like
diuretics
15 (9.1%) 11 (6.7%) 4 (2.4%) 149 (90.9%) 74 (45.1%) 75 (45.7%)
Beta-blockers 66 (86.8%) 29 (38.2%) 37 (48.7%) 10 (13.2%) 6 (7.9%) 4 (5.3%)
Alpha-blockers 19 (44.2%) 10 (23.3%) 9 (20.9%) 24 (55.8%) 12 (27.9%) 12 (27.9%)
Other antihypertensives 22 (73.3%) 7 (23.3%) 15 (50.0%) 8 (26.7%) 4 (13.3%) 4 (13.3%)
ACE  angiotensin converting enzyme; DDD  defined daily dose.
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baseline blood pressures. This supports recommendations for the
use of calcium channel blockers as a first line therapy for
hypertension in older patients and suggests these might be
avoided as a target for deprescribing. These analyses were
exploratory in nature and further larger, appropriately
powered studies are needed to confirm these findings in older
patients with multi-morbidity and polypharmacy.
Strengths and Limitations
This is the first analysis of medication reduction by
antihypertensive drug class and medication dose using data
from a randomized controlled trial (Sheppard et al., 2020c).
The trial was successful in recruiting a mildly frail population
with multi-morbidity and polypharmacy, representative of older
patients attending primary care in England. This was a post-hoc,
exploratory analysis, which may have been underpowered to
show definitive associations between drug classes, particularly
for alpha-blockers and ‘other’ antihypertensives that were chosen
for withdrawal in less than 50 trial participants. Since multiple
statistical analyses were conducted, the significant associations
between withdrawal of calcium channel blockers, higher dose
medications and blood pressure at follow-up may have been
observed by chance and so these results should be interpreted
with caution.
Although follow-up was achieved in 93.8% of participants, the
period of follow-up was short, and so it was not possible to
examine clinical endpoints such as hospitalization, cardiovascular
disease or death at this stage, though the cohort will be followed
up. In addition, although routine prescription of beta-blockers is
often accompanied by monitoring of heart rate, we did not collect
this or related outcomes (e.g. development of atrial fibrillation)
during follow-up, precluding any analyses of these outcomes.
Comparison With Previous Literature
Previous trials of antihypertensive medication reduction have
only attempted medication reduction in up to two thirds of
participants (Moonen et al., 2015; Gulla et al., 2018; Luymes
et al., 2018), had smaller sample sizes (Moonen et al., 2015; Gulla
et al., 2018), examined younger populations (i.e. aged less than
80 years) (Luymes et al., 2018) and lacked comparisons with a
control group to determine the effect of deprescribing on
outcomes (Gulla et al., 2018). This is the first analysis of any
previous trial examining deprescribing by drug class and
medication dose, providing preliminary data which should be
explored in future appropriately powered studies. This might
involve attempting to pool data from previous trials (Moonen
et al., 2015; Gulla et al., 2018; Luymes et al., 2018) to increase the
power to detect effects.
FIGURE 2 | Relative risk of blood pressure control and adverse events in patients reducing antihypertensive medication compared to usual care, by drug class
chosen for withdrawal*. *Since the treating physician’s choice of medication to withdraw was made prior to consent and randomization, data were available for all
randomized participants, even though only half went on to have the medication withdrawn in the trial. RR  relative risk; CI  confidence interval. Generalized linear mixed
model with binomial error and log link, with factors predictive of physician choice of drug to withdraw (see Table 2) and baseline systolic blood pressure, gender,
cognitive function (MoCA Score), EQ-5D-5L Index and Searle Frailty Index as fixed effects.
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Implications for Clinical Practice
Physicians participating in the OPTiMISE trial (Sheppard et al.,
2020c) were given the freedom to choose which medication
should be withdrawn if participants were randomized to the
intervention arm of the trial. Advice was given in the form of a
medication reduction algorithm which recommended reducing
medications in reverse of the C + A + D NICE treatment
algorithm (National Guideline Centre, 2019) i.e.; if a
participant was prescribed three antihypertensive medications
including a thiazide or thiazide-like diuretic, this was
recommended to be removed instead of a renin-angiotensin
system medication or a calcium channel blocker. In the
present analysis, 3 out of 4 patients prescribed a thiazide and
thiazide-like diuretic had this medication chosen for withdrawal
and increasing number of antihypertensive medications
prescribed was one of the strongest predictors of this choice,
suggesting that the medication reduction algorithm was followed
as suggested.
Calcium channel blockers were less likely to be chosen for
medication reduction in patients with higher baseline systolic
blood pressure and despite this, withdrawal of these medications
was associated with a higher likelihood of uncontrolled blood
pressure at follow-up. One explanation for this might be that
these medications were predominantly prescribed at higher
doses, where the blood pressure lowering effect might be
expected to be greater. There is also evidence to suggest that
calcium channel blockers are more effective in older individuals,
leading to recommendations in clinical guidelines that these
should be used as a first line therapy (Williams et al., 2018;
National Guideline Centre, 2019). These findings reinforce
recommendations in the medication withdrawal algorithm
used in the trial, which suggested that these medications
should be considered last for medication withdrawal.
The proportion of patients prescribed beta-blockers at baseline
was relatively high, particularly since patients with a history of
heart failure due to left ventricular dysfunction were excluded
(Sheppard et al., 2018). Given that many participants had been
diagnosed with hypertension for many years, it is possible that
beta-blockers were originally prescribed at a time when they were
recommended as a first line treatment for hypertension (Williams
et al., 2004). Although subsequent guidelines have changed this
recommendation (Mayor, 2006), many patients could have
remained on the same treatment as originally prescribed.
These data show that a high proportion of patients withdrawing
beta-blockers maintained medication reduction at follow-up and
that withdrawal of such medications may be associated with no
change or even a reduction in systolic blood pressure. Beta-
blockers were more likely to be prescribed at lower doses for
patients enrolled into the trial, and selected for medication
reduction if participants were prescribed a higher number of
FIGURE 3 |Mean change in blood pressure in patients reducing antihypertensive medication compared to usual care, by drug class chosen for withdrawal* *Since
the treating physician’s choice of medication to withdraw wasmade prior to consent and randomization, data were available for all randomized participants, even though
only half went on to have the medication withdrawn in the trial. BP  blood pressure; CI  confidence interval Generalized linear mixed model with binomial error and log
link, with factors predictive of physician choice of drug to withdraw (see Table 2) and baseline systolic blood pressure, gender, cognitive function (MoCA Score),
EQ-5D-5L Index and Searle Frailty Index as fixed effects and primary care site as a random effect.
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antihypertensive medications at baseline. Since polypharmacy is
associated with reduced adherence to medications (Smaje et al.,
2018), it is possible that withdrawal of beta-blockers may have
increased an individual’s adherence to their remainingmedications
causing blood pressure to be reduced at follow-up, although one
might expect this to also be the case for withdrawal of any
medication in patients taking multiple antihypertensives.
While withdrawing low-dose beta-blockers with no
resulting increase in blood pressure maybe an appealing
strategy for physicians, it is important to note that beta-
blockers have other cardio-protective properties and may be
indicated for other reasons beyond hypertension, such as
ischemic heart disease, tachycardia and heart failure with
reduced ejection fraction. There was also some evidence to
suggest that withdrawal of low dose medications resulted in an
increase in adverse events, although these varied widely in
terms of severity (e.g. increased blood pressure, chest pain,
infections, ankle swelling, headache and back pain). Only 23
participants (13 in the medication reduction group and 10 in
the usual care group) experienced a serious adverse event
resulting in hospitalization during the trial (Sheppard et al.,
2020c). Until studies with long-term follow-up are conducted,
it is difficult to draw firm conclusions regarding the choice of
medication to withdraw first as part of a deprescribing
intervention.
CONCLUSION
This exploratory analysis found some evidence to suggest
that withdrawal of higher dose calcium channel blockers
should be avoided if the goal is to maintain blood pressure
control. However, low dose beta-blockers may be removed
with little impact on blood pressure at follow-up. More
appropriately powered studies are needed to determine
whether withdrawal of certain drug classes and/or doses are
preferable over others in older patients with multi-morbidity
and polypharmacy.
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